Druggability analysis and structural classification of bromodomain acetyl-lysine binding sites

Journal of Medicinal Chemistry

Volumn 55, Issue 17, 2012, Pages 7346-7359

  Vidler, Lewis R ^a   Brown, Nathan ^a   Knapp, Stefan ^b   Hoelder, Swen ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; GSK 1210151 A; GSK 626762 A; ISCHEMIN; LYSINE; MS 7972; PROTEIN INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; BINDING SITE; CRYSTAL STRUCTURE; DRUG STRUCTURE; EPIGENETICS; LIGAND BINDING; PROTEIN DOMAIN; PROTEIN FAMILY; PROTEIN PROTEIN INTERACTION; SCREENING;

BINDING SITES; LYSINE; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PROTEINS;

EID: 84866338076     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm300346w     Document Type: Article

References (41)

1. Kouzarides, T. Chromatin Modifications and Their Function Cell 2007, 128, 693-705 (Pubitemid 46273577)
2. Jenuwein, T.; Allis, C. D. Translating the Histone Code Science 2001, 293, 1074-1080 (Pubitemid 32758077)
3. Zeng, L.; Zhou, M. M. Bromodomain: An acetyl-lysine binding domain FEBS Lett. 2002, 513, 124-128 (Pubitemid 34242989)
4. Filippakopoulos, P.; Picaud, S.; Mangos, M.; Keates, T.; Lambert, J.-P.; Barsyte-Lovejoy, D.; Felletar, I.; Volkmer, R.; Müller, S.; Gingras, A.-C.; Pawson, T.; Arrowsmith, C.; Knapp, S. Histone Recognition and Large-Scale Structural Analysis of the Human Bromodomain Family Cell 2012, 149, 214-231
5. Mutjaba, S.; Zeng, L.; Zhou, M. M. Structure and acetyl-lysine recognition of the bromodomain Oncogene 2007, 26, 5521-5527 (Pubitemid 47255932)
6. Filippakopoulos, P.; Qi, J.; Picaud, S.; Shen, Y.; Smith, W. B.; Fedorov, O.; Morse, E. M.; Keates, T.; Hickman, T. T.; Felletar, I.; Philpott, M.; Munro, S.; McKeown, M. R.; Wang, Y.; Christie, A. L.; West, N.; Cameron, M. J.; Schwartz, B.; Heightman, T. D.; La Thangue, N.; French, C. A.; Wiest, O.; Kung, A. L.; Knapp, S.; Bradner, J. E. Selective inhibition of BET bromodomains Nature 2010, 468, 1067-1073
7. Chung, C.-w.; Coste, H.; White, J. H.; Mirguet, O.; Wilde, J.; Gosmini, R. L.; Delves, C.; Magny, S. M.; Woodward, R.; Hughes, S. A.; Boursier, E. V.; Flynn, H.; Bouillot, A. M.; Bamborough, P.; Brusq, J.-M. G.; Gellibert, F. J.; Jones, E. J.; Riou, A. M.; Homes, P.; Martin, S. L.; Uings, I. J.; Toum, J.; Clement, C. A.; Boullay, A.-B.; Grimley, R. L.; Blandel, F. M.; Prinjha, R. K.; Lee, K.; Kirilovsky, J.; Nicodeme, E. Discovery and characterization of small molecule inhibitors of the BET family bromodomains J. Med. Chem. 2011, 54, 3827-3838
8. Dawson, M. A.; Prinjha, R. K.; Dittman, A.; Giotopoulos, G.; Bantscheff, M.; Chan, W.-i.; Robson, S. C.; Chung, C.-w.; Hopf, C.; Savitski, M. M.; Huthmacher, C.; Gudgin, E.; Lugo, D.; Beinke, S.; Chapman, T. D.; Roberts, E. J.; Soden, P. E.; Auger, K. R.; Mirguet, O.; Doehner, K.; Delwel, R.; Burnett, A.; Jeffrey, P.; Drewes, G.; Lee, K.; Huntly, B. J. P.; Kouzarides, T. Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia Nature 2011, 478, 529-533
9. Hopkins, A. L.; Groom, C. R. The druggable genome Nature Rev. Drug Discovery 2002, 1, 727-730 (Pubitemid 37361545)
10. Muller, S.; Filippakopoulos, P.; Knapp, S. Bromodomains as therapeutic targets Expert Rev. Mol. Med. 2011, 13, e29
11. Zuber, J.; Shi, J.; Wang, E.; Rappaport, A. R.; Herrmann, H.; Sison, E. A.; Magoon, D.; Qi, J.; Blatt, K.; Wunderlich, M.; Taylor, M. J.; Johns, C.; Chicas, A.; Mulloy, J. C.; Kogan, S. C.; Brown, P.; Valent, P.; Bradner, J. E.; Lowe, S. W.; Vakoc, C. R. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia Nature 2011, 478, 524-528
12. Nicodeme, E.; Jeffrey, K. L.; Schaefer, U.; Beinke, S.; Dewell, S.; Chung, C.-w.; Chandwani, R.; Marazzi, I.; Wilson, P.; Coste, H.; White, J.; Kirilovsky, J.; Rice, C. M.; Lora, J. M.; Prinjha, R. K.; Lee, K.; Tarakhovsky, A. Suppression of inflammation by a synthetic histone mimic Nature 2010, 468, 1119-1123
13. Hewings, D. S.; Wang, M.; Philpott, M.; Fedorov, O.; Uttarkar, S.; Filippakopoulos, P.; Picaud, S.; Vuppusetty, C.; Marsden, B.; Knapp, S.; Conway, S. J.; Heightman, T. D. 3,5-Dimethylisoxazoles Act as Acetyl-lysine-mimetic Bromodomain Ligands J. Med. Chem. 2011, 54, 6761-6770
14. Sachchidanand; Resnick-Silverman, L.; Yan, S.; Mutjaba, S.; Liu, W. J.; Zeng, L.; Manfredi, J. J.; Zhou, M. M. Target structure-based discovery of small molecules that block human p53 and CREB binding protein association Chem. Biol. 2006, 13, 81-90 (Pubitemid 43099926)
15. Borah, J. C.; Mujtaba, S.; Karakikes, I.; Zeng, L.; Muller, M.; Patel, J.; Moshkina, N.; Morohashi, K.; Zhang, W.; Gerona-Navarro, G.; Hajjar, R. J.; Zhou, M. M. A small molecule binding to the coactivator CREB-binding protein blocks apoptosis in cardiomyocytes Chem. Biol. 2011, 4, 531-541
16. Zeng, L.; Li, J.; Muller, M.; Yan, S.; Mujtaba, S.; Pan, C.; Wang, Z.; Zhou, M.-M. Selective Small Molecules Blocking HIV-1 Tat and Coactivator PCAF Association J. Am. Chem. Soc. 2005, 127, 2376-2377 (Pubitemid 40327786)
17. Campagna-Slater, V.; Mok, M. W.; Nguyen, K. T.; Feher, M.; Najmanovich, R.; Schapira, M. Structural Chemistry of the Histone Methyltransferases Cofactor Binding Site J. Chem Inf. Model. 2011, 51, 612-623
18. Santiago, C.; Nguyen, K.; Schapira, M. Druggability of methyl-lysine binding sites J Comput.-Aided. Mol. Des. 2011, 25, 1171-1178
19. Sheridan, R. P.; Maiorov, V. N.; Holloway, M. K.; Cornell, W. D.; Gao, Y. D. Drug-like density: a method of quantifying the "bindability" of a protein target based on a very large set of pockets and drug-like ligands from the Protein Data Bank J. Chem. Inf. Model. 2010, 50, 2029-2040
20. Volkamer, A.; Griewel, A.; Grombacher, T.; Rarey, M. Analyzing the Topology of Active Sites: On the Prediction of Pockets and Subpockets J. Chem. Inf. Model. 2010, 50, 2041-2052
21. Volkamer, A.; Kuhn, D.; Grombacher, T.; Rippmann, F.; Rarey, M. Combining Global and Local Measures for Structure-Based Druggability Predictions J. Chem. Inf. Model. 2012, 52, 360-372
22. DrugEBIlity; EMBL-EBI: Wellcome Trust Genome Campus: Hinxton, Cambridgeshire, CB10 1SD, UK; https://www.ebi.ac.uk/chembl/drugebility/.
23. Krasowski, A.; Muthas, D.; Sarkar, A.; Schmitt, S.; Brenk, R. DrugPred: A Structure-Based Approach To Predict Protein Druggability Developed Using an Extensive Nonredundant Data Set J. Chem. Inf. Model. 2011, 51, 2829-2842
24. Schmidke, P.; Le Guilloux, V.; Maupetit, J.; Tufféry, P. fpocket: online tools for protein ensemble pocket detection and tracking Nucleic Acids Res. 2010, 38, W582-W589
25. Schmidke, P.; Barril, X. Understanding and Predicting Druggability. A High-Throughput Method for Detection of Drug Binding Sites J. Med. Chem. 2010, 53, 5858-5867
26. Cheng, A.; Coleman, R. G.; Smyth, K. T.; Cao, Q.; Soulard, P.; Caffrey, D. R.; Salzberg, A. C.; Huang, E. S. Structure-based maximal affinity model predicts small-molecules druggability Nature Biotechnol. 2007, 25, 71-75 (Pubitemid 46087905)
27. Nayal, M.; Honig, B. On the nature of cavities on protein surfaces: application to the identification of drug-binding sites Proteins 2006, 63, 892-906 (Pubitemid 43765141)
28. SiteMap 2.5; Schrödinger, LLC: 101 SW Main Street, Suite 1300, Portland, OR 97204, U.S.A.; http://www.schrodinger.com/.
29. Halgren, T. A. Identifying and Characterizing Binding Sites and Assessing Druggability J. Chem. Inf. Model. 2009, 49, 377-389
30. Hajduk, P. J.; Huth, J. R.; Tse, C. Predicting protein druggability Drug Discovery Today 2005, 10, 1675-1682 (Pubitemid 41817616)
31. Fauman, E. B.; Rai, B. K.; Huang, E. S. Structure-based druggability assessment-identifying suitable targets for small molecule therapeutics Curr. Opin. Chem. Biol. 2011, 15, 463-468
32. Berman, H. M.; Westbrook, J.; Feng, Z.; Gilliland, G.; Bhat, T. N.; Weissig, H.; Shindyalov, I. N.; Bourne, P. E. The Protein Data Bank Nucleic Acids Res. 2000, 28, 235-242 (Pubitemid 30047768)
33. MOE 2010.10; Chemical Computing Group: Montreal, Quebec, Canada; http://www.chemcomp.com/.
34. Protein Preparation Wizard; Schrödinger, LLC: 101 SW Main Street, Suite 1300, Portland, OR 97204, U.S.A.; http://www.schrodinger.com/.
35. Maestro 9.2; Schrödinger, LLC: 101 SW Main Street, Suite 1300, Portland, OR 97204, U.S.A.; http://www.schrodinger.com/.
36. Aabel 3; Gigawiz Ltd. Co.: P.O. Box 33109, Tulisa, OK 74153, U.S.A.; http://www.gigawiz.com/.
37. iMindMap 5.43 Basic; ThinkBuzan: Regus House, Falcon Drive, Cardiff, CF10 4RU, U.K.; http://thinkbuzan.com/.
38. Hopkins, A. L.; Groom, C. R.; Alex, A. Ligand efficiency: a useful metric for lead selection Drug Discovery Today 2004, 9, 430-431 (Pubitemid 38510559)
39. Philpott, M.; Yang, J.; Tumber, T.; Fedorov, O.; Uttarkar, S.; Filippakopoulos, P.; Picaud, S.; Keates, T.; Felletar, I.; Ciulli, A.; Knapp, S.; Heightman, T. Bromodomain-peptide displacement assays for interactome mapping and inhibitor discovery Mol. BioSyst. 2011, 7, 2899-2908
40. Oltersdorf, T.; Elmore, S. W.; Shoemaker, A. R.; Armstrong, R. C.; Augeri, D. J.; Belli, B. A.; Bruncko, M.; Deckwerth, T. L.; Dinges, J.; Hajduk, P. J.; Joseph, M. K.; Kitada, S.; Korsmeyer, S. J.; Kunzer, A. R.; Letai, A.; Li, C.; Mitten, M. J.; Nettesheim, D. G.; Ng, S.; Nimmer, P. M.; O'Connor, J. M.; Oleksijew, A.; Petros, A. M.; Reed, J. C.; Shen, W.; Tahir, S. K.; Thompson, C. B.; Tomaselli, K. J.; Wang, B.; Wendt, M. D.; Zhang, H.; Fesik, S. W.; Rosenberg, S. H. An inhibitor of Bcl-2 family proteins induces regression of solid tumours Nature 2005, 435, 677-681 (Pubitemid 40825512)
41. Bruncko, M.; Oost, T. K.; Belli, B. A.; Ding, H.; Joseph, M. K.; Kunzer, A.; Martineau, D.; McClellan, W. J.; Mitten, M.; Ng, S. C.; Nimmer, P. M.; Oltersdorf, T.; Park, C. M.; Petros, A. M.; Shoemaker, A. R.; Song, X.; Wang, X.; Wendt, M. D.; Zhang, H.; Fesik, S. W.; Rosenberg, S. H.; Elmore, S. W. Studies leading to potent, dual inhibitors of Bcl-2 and Bcl-xL J. Med. Chem. 2007, 50, 641-662 (Pubitemid 46332978)